Didactics-Management of Recurrent Epithelial Ovarian Cancer

Video Transcription

Video Summary

In this video, Dr. Rajiv discusses the management of recurrent epithelial ovarian cancer. He explains the definitions of platinum sensitivity and resistance based on the time of recurrence after completion of first-line platinum-based therapy. He mentions that re-induction of platinum-based chemotherapy is preferred for platinum-sensitive disease, while conventional therapies are ineffective for resistant disease. He also discusses various chemotherapy options for platinum-sensitive disease, including paclitaxel, chiroplatin, liposomal doxorubicin, and zemcitabine. The addition of bevacizumab to these combinations is also mentioned. For platinum-resistant disease, single-agent sequential therapy is recommended. The use of PARP inhibitors, such as niraparib, olaparib, and rucaparib, is discussed for BRCA-positive tumors. Other treatment options, such as immunotherapy and endocrine therapy, are mentioned, but their efficacy is limited. Dr. Rajiv also highlights the importance of considering resource stratified guidelines, such as those provided by IGCS Eco-Nepal Project, for managing ovarian cancer in countries like Nepal. Lastly, he mentions a promising study on the use of weekly cisplatin and daily oral etoposide in platinum-resistant cases.

Asset Subtitle

Rajeev Sharma
April 2023

Keywords

recurrent epithelial ovarian cancer

platinum sensitivity

platinum resistance

chemotherapy options

PARP inhibitors